CompletedNot Applicable

Study of Predictors of Failure of Sulprostone Treatment in Postpartum Hemorrhage

France300 participantsStarted 2020-10-19

Plain-language summary

The investigators wish to identify potential factors predicting failure of second-line drug treatment (sulproston (Nalador®)): risk factors and factors linked to a failure to take initial care for PPH. A better understanding of the aggravating factors of HPP and more particularly the factors inherent to the initial care would make it possible to think of ways to improve practices.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Major subject (≥18 years old) * Subject having given birth at HUS or CHU Poissy Saint-Germain-en Laye between 01/01/2019 and 31/12/2020 * Subject having presented a postpartum haemorrhage treated with Sulprostone * Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research Exclusion Criteria: * Subject having expressed opposition to participating in the study * Subject under guardianship or guardianship * Subject under safeguard of justice

What they're measuring

This a rétrospective study trayning to identify a potential predictors of failure of second-line drug treatment in the case of severe postpartum hemorrhage

Timeframe: 1 year

Trial details

NCT IDNCT06164236

SponsorUniversity Hospital, Strasbourg, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-04-19

View on ClinicalTrials.gov More Postpartum Hemorrhage trials